ACACA and hyperlipidemia: Clinically, ACC1 is regarded as the most promising target for MAFLD/MASH, while its better regulatory strategies are still needed to pursue for clinical intervention, because hyperlipidemia can be adversely caused by simple ACC1 inhibition strategy (Bian et al, 2022; Goedeke et al, 2018; Zhang et al, 2021).